INCY

Business Context and Reporting Period

Company: Incyte Genomics, Inc. (formerly Incyte Pharmaceuticals, Inc.)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2000
Business Overview: Incyte provides genomics technologies, including proprietary databases (LifeSeq, ZooSeq, LifeExpress), microarray services, and SNP discovery tools to pharmaceutical and biotechnology companies. The company does not intend to develop pharmaceutical products itself but licenses its genomic data and technology to collaborators for drug discovery.

Key Financial Metrics

Note: 2000 results include an extraordinary gain of $3.1 million from the repurchase of convertible notes.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 24% to $194.2 million, driven by new database agreements, the Pfizer partner program, and new products like the in silico SNP (isSNP) service.
• Expense Surge: Total costs and expenses rose to $256.8 million (up 39% from 1999). R&D expenses increased significantly due to bioinformatics, SNP discovery, and internal drug discovery programs. SG&A expenses rose due to sales/marketing growth and legal fees related to patent litigation.
• Capital Structure: In February 2000, the company raised approximately $600 million through a private equity offering ($403 million) and the issuance of $200 million in convertible subordinated notes. This resulted in a substantial increase in cash reserves from $66.9 million to $582.2 million.
• Acquisitions: Completed the acquisition of Proteome, Inc. in December 2000 for approximately $70.8 million in purchase price allocation (cash and stock), adding proteomics capabilities.

Guidance, Outlook, Risks, and Contingencies

• Outlook: Management expects to report a net loss in 2001 due to continued significant investments in internal disease pathway programs, intellectual property, and the integration of Proteome. The company believes current resources are adequate for at least the next 12 months.
• Legal Contingencies (Affymetrix): The company is engaged in significant patent litigation with Affymetrix, Inc. regarding microarray technology. Affymetrix seeks injunctions and damages (potentially tripled for willful infringement). Incyte cannot estimate the potential loss but notes the litigation has resulted in substantial expenses and management distraction. A settlement was reached with GeneLogic in January 2001.
• Key Risks:
  • Profitability: The company has an accumulated deficit of $84.9 million and expects losses to continue as it invests in R&D.
  • Customer Concentration: One customer accounted for 11% of 2000 revenues; loss of major database agreements could materially impact results.
  • Intellectual Property: Uncertainty regarding the scope of patent protection for gene sequences and SNPs, and the risk of infringement claims.
  • Debt Service: The company has $187.8 million in convertible notes due in 2007, requiring annual interest payments of approximately $10.2 million.

Investor Verification Checklist

• Legal Exposure: Verify the status and potential financial impact of the ongoing Affymetrix patent litigation, including the risk of injunctions on microarray services.
• Burn Rate vs. Cash: Confirm that the $582 million cash balance is sufficient to sustain the high R&D burn rate ($192.6 million in 2000) and debt service obligations without further dilution or financing.
• Revenue Recurring Nature: Assess the renewal rates of the 30+ database collaboration agreements, which drive the majority of revenue, and the risk of non-renewal.
• Acquisition Integration: Monitor the integration of Proteome, Inc. and the amortization impact of the $70.8 million in intangible assets on future earnings.
• Debt Covenants: Review the terms of the convertible subordinated notes for any covenants that could be triggered by continued operating losses.